We are live on ! Find out more

Allogene Therapeutics

ALLO

Market cap $722M

2.09 USD

+0.05

2.45%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

2.09

0.00

0%

1 day

2.45%

5 days

-1.42%

1 month

19.43%

3 months

-7.11%

6 months

-24.82%

Year to date

54.81%

1 year

80.17%

5 years

-91.43%

10 years

-91.64%

About: Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Employees: 152

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 54.5%

Negative 9.1%

Zacks Investment Research

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Allogene Therapeutics Q2 Earnings Call Highlights

Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.

Allogene Therapeutics Q2 Earnings Call Highlights

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2026.

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel's Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Substantial MRD Clearance of 58.3%, with a 97.7% Median Decrease in Plasma ctDNA at Day 45, Compared With a 26.6% Median Increase in the Observation Arm Cema-Cel Was Well-Tolerated, With Most Patients Managed in the Outpatient Setting and No Hospitalizations for Treatment-Related Adverse Events FDA Also Granted Fast Track Designation to Cema-Cel for the ALPHA3 Development Program RMAT and Fast Track Status Enable Enhanced FDA Engagement and Support Potential Expedited Development and Review Pathways SOUTH SAN FRANCISCO, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cemacabtagene ansegedleucel (cema-cel) for the treatment of adult patients with large B-cell lymphoma (LBCL) who, at the completion of first-line (1L) therapy, are in complete or partial response suitable for observation but test positive for minimal residual disease (MRD).

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached Safety Profile was Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HS ALLO-316 Demonstrated Robust Expansion and Tumor Infiltration Following Standard Lymphodepletion, Validating the Dagger ® Technology as a Next-Generation Allogeneic CAR T Platform SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of complete Phase 1 data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma (RCC) in the Journal of Clinical Oncology.

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation

Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.

Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation

Zacks Investment Research

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

See News Rankings

Price charts implemented using Lightweight Charts™